PIRIDE M 1 TAB is a fixed-dose oral antidiabetic medication that combines two powerful agents: Glimepiride 1 mg and Metformin Hydrochloride 500 mg in sustained-release form. This synergistic formulation is designed to provide comprehensive glycemic control in patients with Type 2 Diabetes Mellitus who are either inadequately controlled on monotherapy or are initiating dual therapy for better results.

Glimepiride belongs to the sulfonylurea class and stimulates the release of insulin from functional pancreatic beta cells. Its action is glucose-dependent, meaning it enhances insulin secretion primarily in the presence of elevated blood glucose levels, thus reducing the risk of hypoglycemia compared to older sulfonylureas. Metformin, a biguanide, complements this effect by improving insulin sensitivity, decreasing hepatic glucose production, and enhancing peripheral glucose uptake. The sustained-release format of Metformin in PIRIDE M 1 TAB ensures a steady and prolonged action with improved gastrointestinal tolerability.

This combination targets the core pathophysiological defects in Type 2 Diabetes, namely insulin resistance and beta-cell dysfunction. Glimepiride acts on the pancreas, while Metformin primarily acts on the liver and muscle tissues. As a result, PIRIDE M 1 TAB offers a well-rounded pharmacological approach that improves fasting and postprandial blood glucose levels. It is suitable for once-daily dosing, typically administered with the first major meal of the day, making it convenient for long-term use and improving patient adherence.

Bluepill Express ensures the manufacturing of PIRIDE M 1 TAB in WHO-GMP and ISO-certified units, following stringent quality control protocols. Each tablet undergoes rigorous testing for assay, dissolution, uniformity, and stability, ensuring therapeutic accuracy and compliance with international pharmacopeial standards. The sustained-release technology used in Metformin production offers improved gastrointestinal tolerability, reduced peak plasma fluctuations, and enhanced patient comfort, especially in those starting dual therapy.

PIRIDE M 1 TAB is indicated for adults with Type 2 Diabetes Mellitus where diet, exercise, and single-drug regimens have not resulted in adequate glycemic control. It may also be considered a first-line treatment in cases where initial blood glucose levels are significantly elevated. Clinical studies have shown that fixed-dose combinations like PIRIDE M 1 reduce glycemic variability and may provide cardiovascular and metabolic benefits when used appropriately.